Topic
Regadenoson
About: Regadenoson is a research topic. Over the lifetime, 441 publications have been published within this topic receiving 8059 citations. The topic is also known as: CVT-3146 & Lexiscan®.
Papers published on a yearly basis
Papers
TL;DR: The biology of adenosine signalling is focused on to identify hurdles in the development of additional pharmacological compounds targeting adenoine receptors and discuss strategies to overcome these challenges.
Abstract: Adenosine signalling has long been a target for drug development, with adenosine itself or its derivatives being used clinically since the 1940s. In addition, methylxanthines such as caffeine have profound biological effects as antagonists at adenosine receptors. Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors. There is strong evidence that adenosine has a functional role in many diseases, and several pharmacological compounds specifically targeting individual adenosine receptors — either directly or indirectly — have now entered the clinic. However, only one adenosine receptor-specific agent — the adenosine A2A receptor agonist regadenoson (Lexiscan; Astellas Pharma) — has so far gained approval from the US Food and Drug Administration (FDA). Here, we focus on the biology of adenosine signalling to identify hurdles in the development of additional pharmacological compounds targeting adenosine receptors and discuss strategies to overcome these challenges.
843 citations
TL;DR: Medicinal chemical approaches have been applied to all four of the adenosine receptor (AR) subtypes to create selective agonists and antagonists for each to facilitate research on therapeutic applications of modulating the ARs and in some cases has provided clinical candidates.
436 citations
TL;DR: This phase 3 trial shows that regadenoson provides diagnostic information comparable to a standard adenosine infusion, and there were no serious drug-related side effects, and regadenoon was better tolerated than adenoine.
344 citations
University of Amsterdam1, Academy of Athens2, Guy's Hospital3, Hannover Medical School4, University of Zurich5, Autonomous University of Barcelona6, Medical University of Vienna7, Ruhr University Bochum8, Lund University9, Bispebjerg Hospital10, University of Caen Lower Normandy11, Leiden University Medical Center12, University Medical Center Groningen13
TL;DR: The major changes from the updated 2015 procedural guidelines for radionuclide myocardial perfusion imaging are highlighted, focusing on the important changes related to new instrumentation with improved image information and the possibility to reduce radiation exposure.
Abstract: Since the publication of the European Association of Nuclear Medicine (EANM) procedural guidelines for radionuclide myocardial perfusion imaging (MPI) in 2005, many small and some larger steps of progress have been made, improving MPI procedures. In this paper, the major changes from the updated 2015 procedural guidelines are highlighted, focusing on the important changes related to new instrumentation with improved image information and the possibility to reduce radiation exposure, which is further discussed in relation to the recent developments of new International Commission on Radiological Protection (ICRP) models. Introduction of the selective coronary vasodilator regadenoson and the use of coronary CT-contrast agents for hybrid imaging with SPECT/CT angiography are other important areas for nuclear cardiology that were not included in the previous guidelines. A large number of minor changes have been described in more detail in the fully revised version available at the EANM home page: http://eanm.org/publications/guidelines/2015_07_EANM_FINAL_myocardial_perfusion_guideline.pdf .
331 citations
TL;DR: This review provides an update of the A2A ligands that are undergoing or have undergone clinical studies, including the two currently marketed agonists adenosine and regadenoson.
Abstract: The adenosine A2A receptor is a G-protein-coupled receptor (GPCR) that has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. Herein we describe adenosine A2A receptor distribution, signaling pathways, pharmacology, and molecular structure, followed by a summary and SAR discussion of the most relevant series of adenosine A2A agonists and antagonists. This review also provides an update of the A2A ligands that are undergoing or have undergone clinical studies, including the two currently marketed agonists adenosine and regadenoson.
284 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2025 | 5 |
| 2024 | 13 |
| 2023 | 15 |
| 2022 | 32 |
| 2021 | 30 |
| 2020 | 35 |